Your search returned 2 results.

Results
	1.	Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study. [electronic resource] by Higgins, M Curigliano, G Dieras, V Kuemmel, S Kunz, G Fasching, P A Campone, M Bachelot, T Krivorotko, P Chan, S Ferro, A Schwartzberg, L Gillet, M De Sousa Alves, P M Wascotte, V Lehmann, F F Goss, P Producer: 20171207 In: Breast cancer research and treatment vol. 162 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study. [electronic resource] by Gutzmer, R Rivoltini, L Levchenko, E Testori, A Utikal, J Ascierto, P A Demidov, L Grob, J J Ridolfi, R Schadendorf, D Queirolo, P Santoro, A Loquai, C Dreno, B Hauschild, A Schultz, E Lesimple, T P Vanhoutte, N Salaun, B Gillet, M Jarnjak, S De Sousa Alves, P M Louahed, J Brichard, V G Lehmann, F F Publication details: ESMO open 2016 In: ESMO open vol. 1 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)

Refine your search